Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Australian Survey Reveals Biosimilar Awareness, Switching Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients were less concerned about being prescribed a biosimilar if it was a new prescription or "if efficacy on the reference brand had waned." Medical professionals' concerns related to effectiveness, impact on patient outcomes, and switching.


Related Content

Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged